Benchtop Bioreactors Market Report 2026

The benchtop bioreactors market size has grown rapidly in recent years. It will grow from $1.08 billion in 2025 to $1.19 billion in 2026 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to increasing investment in life sciences research, growth of academic and research institutes, reliance on small-scale fermentation systems, rising pharmaceutical r&d activities, growing demand for controlled laboratory environments.

The benchtop bioreactors market size is expected to see rapid growth in the next few years. It will grow to $1.75 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to expansion of biologics and biosimilar development, adoption of automated and continuous bioreactors, rising focus on personalized medicine research, increasing collaboration with cros, advancements in bioprocessing technologies. Major trends in the forecast period include rising adoption of benchtop bioreactors in research and development, growing demand for single-use and modular bioreactor systems, increasing focus on process optimization and yield improvement, expansion of cell culture and microbial fermentation studies, rising use of benchtop bioreactors in training and academic research.

The growing adoption of gene therapies is expected to drive the expansion of the benchtop bioreactors market in the coming years. Gene therapy is a medical approach that involves altering, replacing, or repairing defective genes to treat or prevent diseases. The rising demand for gene therapy is primarily driven by advances in genetic sequencing and diagnostic technologies, which allow for accurate identification of disease-causing genes and enable targeted therapeutic interventions. Benchtop bioreactors play a critical role in accelerating gene therapy development by offering precise process control and efficient production of gene-modified cells. They facilitate rapid research activities and small-scale manufacturing while enhancing process consistency and speed. For example, in December 2024, the American Society of Gene & Cell Therapy (ASGCT), a US-based nonprofit medical and scientific organization, reported that the US Food and Drug Administration approved six gene therapy products in 2023, an increase from five approvals in 2022. Therefore, the increasing adoption of gene therapies is fueling the growth of the benchtop bioreactors market.

Major companies operating in the benchtop bioreactors market are emphasizing the development of advanced solutions, such as benchtop fermenters, to improve precision, flexibility, and scalability for research and small-scale production. Benchtop fermenters are compact, laboratory-scale bioreactors designed for the controlled cultivation of cells or microorganisms to support experimental and pilot-scale production. For instance, in September 2024, VFL Sciences Private Limited, an India-based biotechnology equipment manufacturer, introduced the GreatFlo series of benchtop fermenters and bioreactors. This modular and versatile range is designed to ensure consistent reproducibility and easy scale-up for fermentation and cell culture applications. The system supports parallel operation with expansion options from 2 to 16 vessels, each with a working volume of 200-500 mL, and features Peltier-based temperature control, exhaust condensers, and 21 CFR Part 11-compliant software for precise control of agitation, pH, dissolved oxygen, and gas mixing.

In May 2024, Advanced Bioprocessing Equipment Corporation (ABEC) Inc., a US-based biopharmaceutical manufacturing company, acquired the bioreactor technology assets of Membio Inc. for an undisclosed amount. Through this acquisition, ABEC aims to enhance its cell-culture manufacturing capabilities by integrating Membio’s innovative benchtop bioreactor platform. Membio Inc. is a Canada-based biotechnology company specializing in the development of scalable cell-culture systems that replicate human physiological conditions.

Major companies operating in the benchtop bioreactors market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, GE Healthcare, Sartorius AG, Eppendorf AG, Solaris Biotech Solutions, IKA-Werke GmbH And Co. KG, GPC Bio USA, Praj HiPurity Systems Limited., PBS Biotech Inc., Bioengineering AG, Broadley‑James Ltd., Infors HT, Solida Biotech, Bbi-biotech GmbH, Applikon Biotechnology B.V., Labfirst Scientific Instruments Co. Ltd, Pharsol Ltd., Uma Pharmatech Machinery.

North America was the largest region in the benchtop bioreactors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the benchtop bioreactors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the benchtop bioreactors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the benchtop bioreactors market by increasing costs of imported components such as sensors, control systems, and stainless-steel materials, affecting overall equipment pricing. Research and development and process development segments are most affected, particularly in regions like North America and Asia-Pacific that depend on global supply chains. These tariffs have caused procurement delays and budget constraints for laboratories. However, they have also encouraged local manufacturing, regional sourcing of components, and innovation in cost-effective benchtop bioreactor designs.

The benchtop bioreactors market research report is one of a series of new reports that provides benchtop bioreactors market statistics, including benchtop bioreactors industry global market size, regional shares, competitors with a benchtop bioreactors market share, detailed benchtop bioreactors market segments, market trends and opportunities, and any further data you may need to thrive in the benchtop bioreactors industry. This benchtop bioreactors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Benchtop bioreactors are small-scale laboratory vessels designed for the controlled cultivation of cells, microorganisms, or tissues. They allow precise regulation of environmental conditions, such as temperature, pH, and oxygen, to optimize growth and product yield. These bioreactors support research and development by providing a stable environment for efficient biological processes and product development.

The main types of benchtop bioreactors include swing-style bioreactors, stirred-tank bioreactors, wave-mixed bioreactors, airlift bioreactors, and bubble column bioreactors. Swing-style bioreactors use a rocking or swinging motion to gently mix and aerate cell cultures, creating a controlled environment for cell growth. Benchtop bioreactors can be categorized by control type into automated, manual, continuous, and batch systems, and are constructed from materials such as stainless steel, glass, plastic, and composites. They are applied in research and development, process development, bioproduction, quality control, and training and education. Key end users include pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations (CROs), and the food and beverage industry.

The benchtop bioreactors market consists of sales of automated benchtop bioreactors, modular and scalable systems, single-use bioreactors, and micro-bioreactors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.